Skip to main content
Medical information Clinical review pending

Genetic Testing

CHRND Gene Multiple Pterygium Syndrome Lethal Type Genetic Test

This genetic test identifies mutations in the CHRND gene associated with lethal multiple pterygium syndrome, using Next Generation Sequencing (NGS) technology. It is important for diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking. Typically 3 to 4 weeks.
Preparation
Confirm with the laboratory before booking. Generally, no special preparation is required for a blood sample.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CHRND Gene Multiple Pterygium Syndrome Lethal Type Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of multiple pterygium syndrome.
  • ✓Patients presenting with symptoms suggestive of multiple pterygium syndrome.
  • ✓Prenatal diagnosis in families with a known history of CHRND-related mutations.
  • ✓Confirmation of diagnosis in suspected cases.
  • ✓Genetic counseling for affected families.
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the CHRND gene associated with lethal multiple pterygium syndrome. This information can aid in diagnosis, prognosis, genetic counseling, and family planning for individuals with suspected or confirmed cases, or those with a family history.
The CHRND Gene Multiple Pterygium Syndrome Lethal Type NGS Genetic DNA Test is a specialized genetic analysis designed to detect mutations within the CHRND gene. These mutations are linked to lethal forms of multiple pterygium syndrome, a condition that can cause significant health issues. Early and accurate diagnosis is crucial for managing the condition effectively. This test utilizes advanced Next Generation Sequencing (NGS) technology to provide a comprehensive analysis of the CHRND gene.

This test specifically looks for alterations in the CHRND gene known to cause lethal types of multiple pterygium syndrome. By examining genetic material obtained from a sample, the test identifies variations that may contribute to the development of this serious condition.

Individuals who may benefit from this test include those with a family history of multiple pterygium syndrome, patients presenting with symptoms suggestive of the condition, or those seeking to understand their genetic risk.

Taking this test can lead to early identification of genetic predispositions, enabling proactive health management. It can also inform family planning decisions and facilitate access to specialized care tailored to the individual's genetic profile.

Results are provided in a detailed report. It is important to discuss the results with a healthcare professional who can interpret the findings and advise on appropriate next steps, including management or treatment options.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Generally, no special preparation is required for a blood sample.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the CHRND gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific regions of the CHRND gene. It may not detect all possible mutations, such as deep intronic changes or large deletions/duplications not detectable by NGS. Results must be interpreted in the context of clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Multiple pterygium syndrome is a group of genetic disorders characterized by the presence of pterygia (web-like folds of skin) in various locations, such as the neck, armpits, and joints. Lethal types are severe and can cause significant health complications.
Individuals with symptoms suggestive of the syndrome, a family history of the condition, or those seeking genetic risk assessment should consider this test.
A sample can be collected as a blood draw, extracted DNA, or a single drop of blood on a special card (FTA card).
The typical turnaround time is approximately 3 to 4 weeks, but please confirm with the laboratory before booking.
Results will indicate whether specific mutations associated with lethal multiple pterygium syndrome were found in the CHRND gene. A healthcare professional should interpret the results in the context of your clinical situation.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp